

**Product Name** : COTI-2

**Synonyms** : COTI2


**Cat No.** : M10200

**CAS Number** : 1039455-84-9

**Molecular Formula** : C<sub>19</sub>H<sub>22</sub>N<sub>6</sub>S

**Formula Weight** : 366.50

**Chemical Name** : 4-(2-pyridinyl)-2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide-1-piperazinecarbothioic acid



**Description** : COTI-2 (COTI2) is an orally available thiosemicarbazone that may act on mutant forms of p53 and PI3K/AKT/mTOR pathway; induces apoptosis in a wide variety of human tumor cells in culture (IC<sub>50</sub>s < 40 nM), inhibits the proliferation of colorectal cancer cell lines more effectively than cetuximab and erlotinib; shows superior activity against tumor, and is safe and well-tolerated in vivo. Ovarian Cancer Phase 1 Clinical

**Pathway** : Apoptosis

**Target** : MDM2-p53

**Receptor** : p53 mutants

**Solubility** : DMSO: 10 mM ( < 1 mg/ml refers to the product slightly soluble or insoluble )

**SMILES** : S=C(N1CCN(C2=NC=CC=C2)CC1)N/N=C3CCCC4=C\3N=CC=C4

**Storage** : (-20°C)

**Stability** : ≥ 2 years

**Reference** :

1. Salim KY, et al. *Oncotarget*. 2016 Jul 5;7(27):41363-41379. | 2. Duffy MJ, et al. *Eur J Cancer*. 2017 Jul 27;83:258-265. | 3. Heffeter P, et al. *Antioxid Redox Signal*. 2018 Jan 15. doi: 10.1089/ars.2017.7487.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE